Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Eli Lilly's pill works in a similar way to Wegovy, Ozempic, and Novo Nordisk's diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person's appetite and regulate blood sugar.

I believe Eli Lilly will not face any threats of loss of exclusivity for its key medications in the next five years, except Trulicity (dulaglutide), a GLP-1 receptor agonist whose US compound ...

Eli Lilly has emerged as a popular growth ... used to treat chronic weight management and diabetes. While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility. Evan ...

While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what Lilly's business looks like beyond weight loss ...